PTC Therapeutics (PTCT) Reports Q2 Loss, Beats Revenue Estimates

PTC Therapeutics (PTCT) came out with a quarterly loss of $0.83 per share versus the Zacks Consensus Estimate of a loss of$ 1.07. This compares to a loss of $1.16 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +22.43%. A quarter ago, it was expected that this biopharmaceutical company would post a loss of$ 1.08 per share when it actually produced earnings of $10.04, delivering a surprise of +1029.63%.Over the last four quarte ...